Focused On-demand Library for RNA N6-adenosine-methyltransferase METTL16

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q86W50

UPID:

MET16_HUMAN

Alternative names:

Methyltransferase 10 domain-containing protein; Methyltransferase-like protein 16; N6-adenosine-methyltransferase METTL16; U6 small nuclear RNA (adenine-(43)-N(6))-methyltransferase

Alternative UPACC:

Q86W50; D3DTI8; Q86TE5; Q96T16; Q9BVG7

Background:

RNA N6-adenosine-methyltransferase METTL16 is a pivotal enzyme in RNA processing, specifically targeting adenosine residues for methylation. This protein plays a crucial role in S-adenosyl-L-methionine homeostasis, influencing the expression of MAT2A transcripts. METTL16's unique ability to methylate a select subset of mRNAs and U6 snRNAs, contingent upon specific sequence and structural prerequisites, underscores its specificity and importance in RNA metabolism.

Therapeutic significance:

Understanding the role of RNA N6-adenosine-methyltransferase METTL16 could open doors to potential therapeutic strategies.